286 related articles for article (PubMed ID: 33131194)
21. Role of C1q-binding anti-HLA antibodies as a predictor of lung allograft outcome.
Brugière O; Roux A; Le Pavec J; Sroussi D; Parquin F; Pradère P; Dupin C; Bunel V; Mourin G; Jebrak G; Dauriat G; Castier Y; Mordant P; Lortat-Jacob B; Jean-Baptiste S; Mal H; Suberbielle C; Gautreau C; Caillat-Zucman S; Cazes A; Thabut G; Taupin JL
Eur Respir J; 2018 Aug; 52(2):. PubMed ID: 29976654
[TBL] [Abstract][Full Text] [Related]
22. Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients.
Fichtner A; Süsal C; Höcker B; Rieger S; Waldherr R; Westhoff JH; Sander A; Opelz G; Tönshoff B
Pediatr Nephrol; 2016 Jul; 31(7):1157-66. PubMed ID: 26928311
[TBL] [Abstract][Full Text] [Related]
23. C1q Binding Activity of De Novo Donor-specific HLA Antibodies in Renal Transplant Recipients With and Without Antibody-mediated Rejection.
Yell M; Muth BL; Kaufman DB; Djamali A; Ellis TM
Transplantation; 2015 Jun; 99(6):1151-5. PubMed ID: 25839705
[TBL] [Abstract][Full Text] [Related]
24. Non-Complement-Binding De Novo Donor-Specific Anti-HLA Antibodies and Kidney Allograft Survival.
Guidicelli G; Guerville F; Lepreux S; Wiebe C; Thaunat O; Dubois V; Visentin J; Bachelet T; Morelon E; Nickerson P; Merville P; Taupin JL; Couzi L
J Am Soc Nephrol; 2016 Feb; 27(2):615-25. PubMed ID: 26047793
[TBL] [Abstract][Full Text] [Related]
25. Evaluation of C1q Status and Titer of De Novo Donor-Specific Antibodies as Predictors of Allograft Survival.
Wiebe C; Gareau AJ; Pochinco D; Gibson IW; Ho J; Birk PE; Blydt-Hansen T; Karpinski M; Goldberg A; Storsley L; Rush DN; Nickerson PW
Am J Transplant; 2017 Mar; 17(3):703-711. PubMed ID: 27539748
[TBL] [Abstract][Full Text] [Related]
26. Impact of C1q fixing donor-specific antibodies on renal transplant outcome.
Baranwal AK; Goswami S; Agarwal SK; Kaur G; Mehra NK
Scand J Immunol; 2021 Jul; 94(1):e13048. PubMed ID: 33914934
[TBL] [Abstract][Full Text] [Related]
27. Detection of Complement-binding Donor-specific Antibodies, Not IgG-antibody Strength Nor C4d Status, at Antibody-mediated Rejection Diagnosis Is an Independent Predictor of Kidney Graft Failure.
Malheiro J; Santos S; Tafulo S; Dias L; Martins S; Fonseca I; Almeida M; Pedroso S; Beirão I; Castro-Henriques A; Cabrita A
Transplantation; 2018 Nov; 102(11):1943-1954. PubMed ID: 29757900
[TBL] [Abstract][Full Text] [Related]
28. Development of de novo HLA donor specific antibodies (HLA-DSA), HLA antibodies (HLA-Ab) and allograft rejection post blood transfusion in kidney transplant recipients.
Jalalonmuhali M; Carroll RP; Tsiopelas E; Clayton P; Coates PT
Hum Immunol; 2020 Jul; 81(7):323-329. PubMed ID: 32327243
[TBL] [Abstract][Full Text] [Related]
29. Understanding the Correlation Between DSA, Complement Activation, and Antibody-Mediated Rejection in Heart Transplant Recipients.
Zhang Q; Hickey M; Drogalis-Kim D; Zheng Y; Gjertson D; Cadeiras M; Khuu T; Baas AS; Depasquale EC; Halnon NJ; Perens G; Alejos J; Cruz D; Ali N; Shemin R; Kwon M; Fishbein MC; Ardehali A; Deng M; Reed EF
Transplantation; 2018 Oct; 102(10):e431-e438. PubMed ID: 29916988
[TBL] [Abstract][Full Text] [Related]
30. Impact of alloantibody strength in crossmatch negative DSA positive kidney transplantation.
Wu P; Jin J; Everly MJ; Lin C; Terasaki PI; Chen J
Clin Biochem; 2013 Oct; 46(15):1389-93. PubMed ID: 23726814
[TBL] [Abstract][Full Text] [Related]
31. Complement-binding anti-HLA antibodies are independent predictors of response to treatment in kidney recipients with antibody-mediated rejection.
Viglietti D; Bouatou Y; Kheav VD; Aubert O; Suberbielle-Boissel C; Glotz D; Legendre C; Taupin JL; Zeevi A; Loupy A; Lefaucheur C
Kidney Int; 2018 Oct; 94(4):773-787. PubMed ID: 29801667
[TBL] [Abstract][Full Text] [Related]
32. Failure to remove de novo donor-specific HLA antibodies is influenced by antibody properties and identifies kidney recipients with late antibody-mediated rejection destined to graft loss - a retrospective study.
Cioni M; Nocera A; Tagliamacco A; Basso S; Innocente A; Fontana I; Magnasco A; Trivelli A; Klersy C; Gurrado A; Ramondetta M; Boghen S; Catenacci L; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Ginevri F; Comoli P
Transpl Int; 2019 Jan; 32(1):38-48. PubMed ID: 30076765
[TBL] [Abstract][Full Text] [Related]
33. Complement (C1q) Binding De Novo Donor-Specific Antibodies and Cardiac-Allograft Vasculopathy in Pediatric Heart Transplant Recipients.
Das BB; Lacelle C; Zhang S; Gao A; Fixler D
Transplantation; 2018 Mar; 102(3):502-509. PubMed ID: 28885488
[TBL] [Abstract][Full Text] [Related]
34. Complement-Binding Donor-Specific Anti-HLA Antibodies and Risk of Primary Graft Failure in Hematopoietic Stem Cell Transplantation.
Ciurea SO; Thall PF; Milton DR; Barnes TH; Kongtim P; Carmazzi Y; López AA; Yap DY; Popat U; Rondon G; Lichtiger B; Aung F; Afshar-Kharghan V; Ma Q; Fernández-Viña M; Champlin RE; Cao K
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1392-8. PubMed ID: 25985919
[TBL] [Abstract][Full Text] [Related]
35. Donor-specific antibody characteristics, including persistence and complement-binding capacity, increase risk for chronic lung allograft dysfunction.
Iasella CJ; Ensor CR; Marrari M; Mangiola M; Xu Q; Nolley E; Moore CA; Morrell MR; Pilewski JM; Sanchez PG; McDyer JF; Zeevi A
J Heart Lung Transplant; 2020 Dec; 39(12):1417-1425. PubMed ID: 32981841
[TBL] [Abstract][Full Text] [Related]
36. Kidney Intragraft Homing of De Novo Donor-Specific HLA Antibodies Is an Essential Step of Antibody-Mediated Damage but Not Per Se Predictive of Graft Loss.
Nocera A; Tagliamacco A; Cioni M; Innocente A; Fontana I; Barbano G; Carrea A; Ramondetta M; Sementa A; Basso S; Quartuccio G; Klersy C; Bertocchi M; Verrina E; Garibotto G; Ghiggeri GM; Cardillo M; Comoli P; Ginevri F
Am J Transplant; 2017 Mar; 17(3):692-702. PubMed ID: 27501275
[TBL] [Abstract][Full Text] [Related]
37. Donor-specific anti-HLA antibodies in pediatric renal transplant recipients with creeping creatinine: Prevalence, histological correlations, and impact on patient and graft survival.
Monteverde ML; Chaparro A; Goldberg J; Marcos CY; Padros K; Balbarrey Z; Briones L; Rush D
Pediatr Transplant; 2015 Nov; 19(7):684-90. PubMed ID: 26212912
[TBL] [Abstract][Full Text] [Related]
38. Donor-specific HLA alloantibodies: Impact on cardiac allograft vasculopathy, rejection, and survival after pediatric heart transplantation.
Tran A; Fixler D; Huang R; Meza T; Lacelle C; Das BB
J Heart Lung Transplant; 2016 Jan; 35(1):87-91. PubMed ID: 26422083
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of the current post-transplantation Human Leukocyte Antigen antibody screening in pediatric renal transplant recipients.
Demirok A; Ranzijn C; Lardy J; Florquin S; Bouts A
Pediatr Transplant; 2019 Mar; 23(2):e13338. PubMed ID: 30635959
[TBL] [Abstract][Full Text] [Related]
40. Effect of C1q-binding donor-specific anti-HLA antibodies on the clinical outcomes of patients after renal transplantation: A systematic review and meta-analysis.
Kang ZY; Liu C; Liu W; Li DH
Transpl Immunol; 2022 Jun; 72():101566. PubMed ID: 35257893
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
